Blepharospasm
Conditions
Brief summary
The purpose of this survey is to collect detailed information on patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA, including how often they are treated with botulinum toxin, how long their treatment lasts, how satisfied they are with their treatment, and if there is any improvement in their symptoms with the treatment.
Detailed description
This study is open to males and females \> 18 years and \< 81 years with a clinical diagnosis of blepharospasm.
Interventions
OTHERNo intervention- only one time survey
Sponsors
Merz North America, Inc.
Merz Pharmaceuticals GmbH
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 81 Years
Healthy volunteers
No
Inclusion criteria
* Male or female subject aged \> 18 years and \< 81 years * Documented clinical diagnosis of blepharospasm * Currently receiving incobotulinumtoxinA, abobotulinumtoxinA or onabotulinumtoxinA
Exclusion criteria
* Previous treatment with rimabotulinumtoxinB in the last 2 treatment cycles
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Botulinum Toxin Treatment Information | This is a single, structured interview about experiences with Botulinum Toxins | The following information for patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA, or onabotulinumtoxinA treatment is collected: (1) botulinum treatment information such as intervals for botulinum injections, physician's rationale for injection interval, overall experience with botulinum toxin injections (onset, maximum effect, decline of effect), current injection cycle experience (current satisfaction, satisfaction at maximum effect, and visual analog scale (VAS) of current health status); and (2) disability status using the Blepharospasm Disability Index (BSDI) and the Jankovic Rating Scale (JRS) |
Countries
United States
Outcome results
None listed